Latest Insider Transactions at Nuvalent, Inc. (NUVL)
This section provides a real-time view of insider transactions for Nuvalent, Inc. (NUVL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuvalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuvalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2026
|
James Richard Porter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+12.46%
|
-
|
|
Jan 07
2026
|
Alexandra Balcom Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+14.99%
|
-
|
|
Jan 07
2026
|
Christopher Durant Turner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+19.42%
|
-
|
|
Jan 07
2026
|
Deborah Ann Miller Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+22.69%
|
-
|
|
Jan 07
2026
|
Darlene Noci Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+23.14%
|
-
|
|
Jan 07
2026
|
Henry E. Pelish Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+17.35%
|
-
|
|
Jan 06
2026
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
9,543
-1.11%
|
$925,671
$97.49 P/Share
|
|
Jan 06
2026
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,181
-1.26%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,181
-1.85%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,589
-1.96%
|
$251,133
$97.49 P/Share
|
|
Jan 06
2026
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,181
-2.47%
|
$308,557
$97.49 P/Share
|
|
Jan 06
2026
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,664
-1.31%
|
$258,408
$97.49 P/Share
|
|
Jan 05
2026
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
17,890
-1.49%
|
$1,735,330
$97.35 P/Share
|
|
Jan 05
2026
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,236
-1.21%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Christopher Durant Turner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,236
-1.73%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,363
-2.29%
|
$423,211
$97.35 P/Share
|
|
Jan 05
2026
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,236
-2.27%
|
$410,892
$97.35 P/Share
|
|
Jan 05
2026
|
Henry E. Pelish Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,496
-0.89%
|
$242,112
$97.35 P/Share
|
|
Jan 02
2026
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-5.92%
|
$1,000,000
$100.76 P/Share
|
|
Jan 02
2026
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+14.47%
|
$180,000
$18.93 P/Share
|
|
Dec 30
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.89%
|
$400,000
$100.52 P/Share
|
|
Dec 30
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$108,000
$27.85 P/Share
|
|
Dec 22
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,500
+27.9%
|
$34,500
$1.08 P/Share
|
|
Dec 22
2025
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,085
+6.68%
|
$5,085
$1.08 P/Share
|
|
Dec 19
2025
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
57,000
+15.7%
|
$0
$0.65 P/Share
|
|
Dec 10
2025
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
2,837
+50.0%
|
-
|
|
Dec 08
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,084
-5.75%
|
$779,240
$110.81 P/Share
|
|
Nov 28
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-3.88%
|
$432,000
$108.29 P/Share
|
|
Nov 28
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$108,000
$27.85 P/Share
|
|
Nov 24
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
1,650
-0.2%
|
$179,850
$109.15 P/Share
|
|
Nov 24
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
5,850
-0.11%
|
$637,650
$109.15 P/Share
|
|
Nov 24
2025
|
James E Flynn Director |
SELL
Open market or private sale
|
Indirect |
742,574
-4.28%
|
$70,544,530
$95.44 P/Share
|
|
Nov 18
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
729
-0.59%
|
$75,816
$104.08 P/Share
|
|
Nov 18
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
729
+1.15%
|
$52,488
$72.35 P/Share
|
|
Nov 17
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
24,200
-12.14%
|
$2,565,200
$106.06 P/Share
|
|
Nov 17
2025
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,200
+24.82%
|
$145,200
$6.89 P/Share
|
|
Nov 17
2025
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,000
-4.55%
|
$1,980,000
$99.76 P/Share
|
|
Nov 17
2025
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.47%
|
$780,000
$39.62 P/Share
|
|
Oct 30
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
21,800
-4.36%
|
$2,201,800
$101.1 P/Share
|
|
Oct 30
2025
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+23.52%
|
$130,800
$6.89 P/Share
|
|
Oct 30
2025
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,000
-1.32%
|
$408,000
$102.26 P/Share
|
|
Oct 30
2025
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+7.14%
|
$108,000
$27.85 P/Share
|
|
Oct 28
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
9,154
-4.31%
|
$915,400
$100.27 P/Share
|
|
Oct 28
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
32,455
-2.29%
|
$3,245,500
$100.27 P/Share
|
|
Oct 27
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
4,046
-1.87%
|
$404,600
$100.23 P/Share
|
|
Oct 27
2025
|
Matthew Shair |
SELL
Open market or private sale
|
Direct |
14,345
-1.0%
|
$1,434,500
$100.23 P/Share
|
|
Oct 20
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,000
-9.24%
|
$470,000
$94.91 P/Share
|
|
Oct 20
2025
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.46%
|
$30,000
$6.89 P/Share
|
|
Oct 16
2025
|
Deborah Ann Miller Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
12,376
-7.19%
|
$1,126,216
$91.47 P/Share
|
|
Oct 16
2025
|
Deborah Ann Miller Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,376
+16.76%
|
$74,256
$6.89 P/Share
|